Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AVXS

AveXis (AVXS) Stock Price, News & Analysis

AveXis logo

About AveXis Stock (NASDAQ:AVXS)

Advanced Chart

Key Stats

Today's Range
$217.83
$217.83
50-Day Range
N/A
52-Week Range
$65.54
$217.94
Volume
222 shs
Average Volume
816,305 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. The company also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases. It has strategic collaboration and license agreements with Nationwide Children's Hospital; The Research Institute at Nationwide Children's Hospital; REGENXBIO Inc.; and Asklepios Biopharmaceutical, Inc. The company was formerly known as BioLife Cell Bank, Inc. and changed its name to AveXis, Inc. in January 2014. AveXis, Inc. was founded in 2010 and is headquartered in Bannockburn, Illinois.

Receive AVXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AveXis and its competitors with MarketBeat's FREE daily newsletter.

AVXS Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

AVXS Stock Analysis - Frequently Asked Questions

AveXis, Inc. (NASDAQ:AVXS) released its quarterly earnings data on Wednesday, May, 9th. The company reported ($6.20) EPS for the quarter, missing the consensus estimate of ($3.32) by $2.88.

AveXis (AVXS) raised $86 million in an initial public offering (IPO) on Thursday, February 11th 2016. The company issued 4,300,000 shares at $19.00-$21.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and BMO Capital Markets and Chardan were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that AveXis investors own include REGENXBIO (RGNX), bluebird bio (BLUE), Bristol Myers Squibb (BMY), Exelixis (EXEL), Mallinckrodt (MNK), AbbVie (ABBV) and BioLife Solutions (BLFS).

Company Calendar

Last Earnings
5/09/2018
Today
6/25/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AVXS
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:AVXS) was last updated on 6/25/2025 by MarketBeat.com Staff
From Our Partners